Document:

EX-10.15

 Exhibit 10.15 
 SECOND AMENDMENT TO OEM LICENSE AGREEMENT 
 This Second
Amendment to the OEM License Agreement (hereinafter referred to as the “Second Amendment”), effective as of February 1st, 2013, by and between THERMOANALYTICS, INC. (the “Company”) located at 23440 Airpark Boulevard, Calumet,
Michigan 49913 and EXA CORPORATION, located at 55 Network Drive, Burlington, Massachusetts 01803 (the “Licensee”) (jointly referred to as the “Parties”; each separately as a “Party”), amends the OEM Licensee Agreement
between the parties dated October 26th, 2006 (the
“Agreement”). as previously amended on June 10, 2011 (the “First Amendment”). 
 WHEREAS, the Parties have been engaged
in a successful OEM license arrangement pursuant to which Licensee has marketed and sold the Derivative Product (as defined in the Agreement); and 
 WHEREAS, the Parties wish to expand the licensing model pursuant to which the Derivative Product may be licensed to End Users to include (in addition to the current Platforms) the Per Hour Offerings (as
defined below) on the terms set forth herein; and 
 WHEREAS, the Parties wish to engage in a joint research and development effort to develop
and improve battery cell modeling capability on the terms set forth herein; 
 NOW, THEREFORE, on consideration of the ongoing obligations set
forth in the Agreement and the mutual covenants set forth in this Second Amendment, the Parties agree as follows: 

1.        Except to the extent defined in this Second Amendment, the capitalized terms used herein are defined in
the Agreement. Except as set forth in this Second Amendment, the Agreement as previously amended shall remain in full force and effect. In the event that there is a conflict between any provision of the Agreement and this Second Amendment, the
conflicting terms set forth in this Second Amendment shall govern. 
 PART I.        THE PER HOUR
OFFERINGS 
 2.        Description of the Per Hour Offerings. In addition to the licensing
model described in the Agreement, which shall remain in effect, the Parties agree that Licensee may offer the Cloud Offering and the Customer Site Offering as described below (together, the “Per Hour Offerings”). 

a.        The Cloud Offering. Licensee may, on a per hour basis, perform or enable
simulations for end users utilizing the Derivative Product either coupled to Licensee’s PowerFLOW product or on a standalone basis from servers hosted by Licensee or its designee (the “Cloud Offering”). Licensee shall be authorized to
run an unlimited number of instances of the Cloud Offering from its data centers and Company hereby licenses Licensee to do so. 

 b.        The Customer Site Offering.
Licensee may, on a per hour basis, enable simulations by end users utilizing the Derivative Product coupled to Licensee’s PowerFLOW product at the end user’s site (the “Customer Site Offering.”) 

3.        Per Hour Offering Compensation. Although Licensee is free to charge any amount for use of the
Cloud Offering or the Customer Site Offering, Company’s Per Hour Offering royalties shall be based on the metrics set forth in this Section 3. As used herein, 
 a.        “Hours” means the total number of core hours that the Cloud Offering and/or the Customer Site Offering are actually in use by paying end users.

 b.        “Paid Block Licenses” means the 7 PowerTHERM4 licenses for the
Derivative Product that Licensee purchases for consulting projects and customer simulations, for which, as of the date of this Second Amendment, Licensee pays $** in annual license fees. 

c.        “Per Hour Offering Hourly Rate” means the per hour license charge for Per
Hour Offering usage, which shall equal the Company’s nominal list price (as set forth in Section 9 of the First Amendment) for an eight-core RadTherm license (that is, one Annual Floating Client + Solver plus seven Annual Floating Parallel
licenses) and a Solid Conduction license divided by ** (that is, ** x ** x **). Which based on the current nominal list prices would equal ($** + ($** x 7) + $**)/** = **/core hour. The per hour license charge for pre-processing (or stand-alone)
usage will be at the same rate per hour. Should Company offer RadTherm licenses in configurations that include more than a total of eight cores per Client + Solver, License may, at its option, calculate the Per Hour Offering Hourly Rate based on the
cost of such licenses and number of available cores. For simulations involving a Thermal Comfort license, the Per Hour Offering Hourly Rate shall be increased by the Company’s current nominal list price for the applicable annual floating
license(s) divided by ** (that is, ** x **). Which based on the current nominal list price would equal $**/** = $**. This definition shall be used solely for the purpose of calculating monies due to Company pursuant to the Per Hour Offerings.
Nothing in this definition shall be construed to limit Licensee or its customers from deploying the Derivative Product in any available core configuration. Consistent with Section 2 of the First Amendment, the Per Hour Offering Hourly Rate for
Academic Licenses shall be ** percent (**%) of the Per Hour Offering Hourly Rate described immediately above. 

d.        “Prepaid Simulation Hours” means the number of hours of simulation capacity
of Licensee’s Paid Block Licenses. 
 e.        “Royalty-Bearing Per Hour
Offering Revenue” means Per Hour Offering Hourly Rate times [Hours minus Prepaid Simulation Hours]. 

**        This material was omitted pursuant to a request for confidential treatment and was separately filed
with the SEC on April 9, 2013 

  
 - 2 -

 Royalties payable to Company based on Royalty-Bearing Per Hour Offering Revenue shall be
computed based on the discount table set forth in Exhibit C (as amended) to the Agreement, provided that, in order to calculate the appropriate discount rate, Royalty-Bearing Per Hour Offering Revenue, revenue from traditional Object Code licenses
and the cost of paid block licenses shall be aggregated. Monthly reports provided pursuant to Article 6.0 of the Agreement shall include the applicable number of Hours, Prepaid Simulation Hours and Royalty-Bearing Per Hour Offering Revenue from the
Per Hour Offerings for the relevant month. 
 4.        Per Hour Offering Support. Company shall
provide support and maintenance for the Per Hour Offerings on the terms set forth in the Agreement. Royalties payable pursuant to the Agreement, including Section 3 of this Second Amendment, shall constitute full payment for such support and
maintenance. 
 5.        Large Customer Discount Pricing. Company understands and agrees that,
in order to obtain the business of certain high volume customers, Licensee may need to offer discounts that may not be feasible at the current Per Hour Offering Hourly Rate. In such cases, Company agrees to negotiate in good faith a discounted Per
Hour Offering Hourly Rate on a customer-by-customer basis. 
 PART II.        THE BATTERY MODEL
PARTNERSHIP 
 6.        Description of Battery Model Software. As used herein, the term
“Battery Model Software” means computer software that enables a user to simulate the electro-thermal performance of various battery cell designs. 
 7.        Battery Model Software Development Program. The Parties, each at their own expense, agree to collaborate on the development of the Battery Model
Software. Each Party will assign one or more employees to participate in the Battery Model Software project (the “Project”), which employees shall constitute the “Team.” The Team will develop and maintain a Battery Model Software
product roadmap and decide on the capabilities to be developed and the development timeline. Utilizing resources from their employers, the members of the Team will make good faith efforts to develop and productize the Battery Model Software. All
decisions of the Team shall be by consensus and each Party reserves the right to dissent from any recommendation of the Team without liability to the other Party. 
 8.        Battery Model Software Validation. The Parties will jointly design the Battery Model Software validation protocols and procedures, including the
validation data set, product testing methodologies and quality assurance protocols. 

9.        Ownership of the Battery Model Software. 

a.        As used herein, “Jointly-Owned Intellectual Property” means (i) any
trade secrets, technical data, designs, concepts, processes, formulae, know-how and information, copyright, patent or other intellectual property rights relating to the Battery Model Software developed pursuant to the Project; “Use” means
the right to use, practice, make, have made, 

  
 - 3 -

 
reproduce, modify, enhance, upgrade, create derivative works, import, export, copy and sell, offer for sale, license and/or sublicense, except as otherwise provided in this Second Amendment.

 b.        Except as set forth herein, the Parties shall jointly own all Jointly-Owned
Intellectual Property and may Use such Jointly-Owned Intellectual Property as it sees fit without the obligation to account to the other Party for such Use, provided that the Parties shall cooperate to seek patent protection for such Jointly-Owned
Intellectual Property pursuant to Section 10 hereof or, where they agree that such patent protection is not appropriate, shall maintain such Jointly-Owned Intellectual Property as trade secrets, only disclosing the same pursuant to an agreement
with appropriate non-disclosure provisions. 
 c.        Notwithstanding the foregoing,
the interface between the Battery Model Software and the Derivative Product shall be owned by Company, subject to a royalty-free license to Licensee to use such interface in connection with using and sublicensing the Derivative Product on the terms
set forth in the Agreement. 
 10.        Patent Reporting and Prosecution. 

a.        At the request of either Party, the Parties shall meet to discuss whether to pursue
patent protection for any inventions or processes included in the Jointly-Owned Intellectual Property and to decide which Party shall take the lead in prosecuting the patents (the “Patent Prosecuting Party”). The cost of patent prosecution
shall be divided equally between the Parties. The Patent Prosecuting Party shall provide the other Party quarterly reports disclosing the status of its efforts to prosecute the patents and patent applications that are a part of the Jointly-Owned
Intellectual Property. In the event that the Patent Prosecuting Party abandons the prosecution or maintenance of any patent of the Jointly-Owned Intellectual Property, including the failure to pay any applicable United States maintenance fee or any
applicable foreign fee, the Patent Prosecuting Party shall first notify the other Party of such intention and the other Party, at its option, may obtain the prosecution file and prosecute or maintain any such patent that is part of such
Jointly-Owned Intellectual Property at its sole cost and expense and, at the other Party’s written request, the former Patent Prosecuting Party shall assign any such patent and all of its right, title and interest therein to the other Party.

 b.        The Patent Prosecuting Party shall direct its patent counsel to provide the
other Party for review and comment all drafts of its patent filings and responses no later than 60 days before the applicable deadline, and all related communications as soon as reasonably possible following receipt or generation. 

c.        The Parties agree that each may use the same patent counsel and/or patent preparation
service and hereby waive any claims of conflict of interest. All reports and communications under this Section which are not public filings or notices are Confidential Information of both Parties. 

d.        In the event that one of the Parties decides that it does not wish to pursue the
prosecution of any patents that are a part of the Jointly-Owned Intellectual Property and such 

  
 - 4 -

 
Jointly-Owned Intellectual Property cannot, by its nature, be maintained as a trade secret, then the other Party shall have the right to prosecute such patents and the first Party shall assign to
the other Party all of its right, title and interest therein. Upon issuance of any such patent, the Party that owns such patent, at the request of the non-owning Party, shall offer the non-owning Party a non-exclusive, royalty-bearing license to Use
the patented invention or process on commercially reasonable terms. 
 11.        Battery Model
Software Information Sharing. Each Party, to the extent permitted by its agreements with its customers, will share technical information about the Battery Model Software obtained from its customers with the other party. 

12.        Infringement Claims. 
 a.        Each Party shall provide the other Party with prompt notice of any alleged, actual or threatened infringement or other improper use of any Jointly-Owned
Intellectual Property of which such Party becomes aware. Upon discovery of such infringement, the Parties agree to confer and decide upon an appropriate course of action. 
 b.        Each Party retains the right, but not the obligation, to take action to institute and prosecute any actions for any infringement or alleged infringement,
and otherwise to take appropriate action with respect to Jointly-Owned Intellectual Property. In the event that both Parties wish to participate in such action, they shall share jointly in the costs and expenses of prosecuting such action and in the
amount recovered through such proceedings. In the event that one Party wishes to take any such action (the “Prosecuting Party”) but the other Party declines to do so, the other Party shall join such proceeding if necessary as a party and
shall provide the Prosecuting Party with all reasonably requested assistance in connection with such proceedings, and the Prosecuting Party shall reimburse the other Party’s reasonable out-of-pocket costs of providing such assistance. The
Prosecuting Party shall be solely responsible for all costs and expenses (including attorneys’ fees) of prosecuting such actions. Unless otherwise agreed in writing, any damages, costs or other amounts recovered through such proceedings for
such purposes shall be retained by the Prosecuting Party. Notwithstanding the foregoing, in no event shall a Party be required to participate in any action that in its reasonable judgment jeopardizes its relationship with an important customer or
vendor. 
 13.        Termination for Convenience. Each Party reserves the right to terminate the
Project without liability to the other Party for any reason or no reason upon thirty (30) days’ written notice to the other Party. Upon the effective date of any such termination, Company and Licensee shall provide each other with copies
of fully documented source code for and technical information about the Battery Model Software that is in its possession. Each Party may use such source code and information to continue its independent development of battery model software or other
software and neither Party shall have any rights to the other Party’s post-termination developments except as may be required by applicable law (for example, the Parties are co-inventors under applicable patent law of a post-termination
invention based on pre-termination research and development activities). Termination of the Project shall not affect the Parties’ rights or obligations under other aspects of the Agreement; the Parties’ rights accruing prior to termination
(for example, ownership and licensing rights to software developed pursuant to the Project prior to termination) shall survive such termination. 

  
 - 5 -

 14.        Applicability of the Agreement. For the avoidance
of doubt, to the full extent applicable, the provisions of the Agreement (including, by way of example but not limitation, Articles 10.0, 11.0, 14.0, 16.0, and 17.0) shall govern the conduct of the Project and the Parties’ legal obligations
thereunder. 
 EACH OF COMPANY AND LICENSEE ACKNOWLEDGES HAVING READ THE TERMS AND CONDITIONS SET FORTH IN THIS SECOND AMENDMENT, UNDERSTANDS
ALL TERMS AND CONDITIONS CONTAINED THEREIN, AND AGREES TO BE BOUND THEREBY. 
  

									
	THERMOANALYTICS, INC.	 		 	EXA CORPORATION
					
	 BY:
	 	 /s/ Keith Johnson
	 		 	BY:	 	 /s/ Edmond L. Furlong

					
	 NAME:
	 	 Keith Johnson
	 		 	NAME:	 	 Edmond L. Furlong

					
	 TITLE:
	 	 CEO/President
	 		 	TITLE:	 	 COO/CFO

					
	 PHONE:
	 	 906-482-9560
	 		 	PHONE:	 	 781-560-0220

  
 - 6 -Exhibit 10.1

 Exhibit 10.1 
 THIS MUTUAL AGREEMENT TO TERMINATE the distribution and licensing agreement dated February 3, 2011 is made and entered into as of April 2nd, 2013 (hereinafter the
“Termination Agreement”). 
  

	BETWEEN:	THERATECHNOLOGIES INC., a company incorporated under the laws of the Province of Québec, having its principal place of business at 2310 Alfred-Nobel
Blvd., Montreal, Québec, Canada H4S 2B4; 

  

	 	(hereafter referred to as “Theratechnologies”); 

  

	AND:	THERATECHNOLOGIES EUROPE INC., a company incorporated under the laws of the Province of Québec, having its principal place of business at 2310
Alfred-Nobel Blvd, Montreal, Québec, Canada H4S 2B4; 

  

	 	(hereinafter referred to as “Thera Europe”); 

  

	AND:	 FERRER INTERNACIONAL, S.A., a corporation duly constituted under the laws of Spain, having its principal place of business at Diagonal 549,
5th Floor 08029, Barcelona, Spain;

  

	 	(hereinafter referred to as “Ferrer”). 

 WHEREAS, the Parties have entered into a distribution and licensing agreement on February 3, 2011 (the “Agreement”); and 

WHEREAS, the Parties have mutually agreed to terminate the Agreement;  

NOW, THEREFORE, IN CONSIDERATION OF THE FOREGOING PREMISES, THE PARTIES HERETO, INTENDING TO BE LEGALLY BOUND, AGREE AS FOLLOWS: 

1.       All capitalized terms used herein that are not defined in this Termination Agreement shall have
the meaning ascribed thereto in the Agreement. 
 2.       The Parties hereby terminate the
Agreement as of the date hereof (hereinafter the “Termination Date”). In furtherance of the foregoing, as of the Termination Date, all licenses and sublicenses granted to Ferrer under the Agreement in connection with the
Commercialization of the Product in the Territory shall immediately and automatically terminate. 

3.       The Parties hereby acknowledge that they will continue to be bound by the terms of
Section 14.9, including the articles and sections referred to under Section 14.9.1(a) of the Agreement, and the definitions in Article 1 thereof for the sole purposes of construing this Termination Agreement.

 4.       The Parties hereby agree that Theratechnologies will
issue the press release attached as Schedule “A” to this Termination Agreement no later than one (1) Business Day after the Termination Date. In addition, Ferrer acknowledges that this Termination Agreement may be filed by
Theratechnologies with securities regulatory authorities in connection with its continuous disclosure obligations under securities regulation. 
 5.       Ferrer, acting for itself, its successors and assigns, hereby releases and forever discharges Theratechnologies and Thera Europe and its Affiliates, and their
respective past and present directors, officers, agents, representatives and employees from any and all claims, debts, demands, contracts, agreements, damages, actions, causes of action, and all liabilities of any kind or nature whatsoever in law,
in equity or otherwise existing up to the present time or which is not now known or anticipated but may arise in the future, in any way related to or arising from the Agreement, including the termination thereof as of the Termination Date, except
with respect to the surviving obligations described in Section 3 of this Termination Agreement. 

6.       Theratechnologies and Thera Europe, acting respectively for themselves, their successors and
assigns, hereby release and forever discharge Ferrer and its Affiliates, and their respective past and present directors, officers, agents, representatives and employees from any and all claims, debts, demands, contracts, agreements, damages,
actions, causes of action, and all liabilities of any kind or nature whatsoever in law, in equity or otherwise existing up to the present time or which is not now known or anticipated but may arise in the future, in any way related to or arising
from the Agreement, including the termination thereof as of the Termination Date, except with respect to the surviving obligations described in Section 3 of this Termination Agreement. 

7.       Each Party hereto agrees to do such further acts and things and to execute and deliver such
additional agreements, powers and instruments as the other may reasonably request to carry into effect the terms, provisions and purposes of this Termination Agreement or to better assure and confirm their respective rights hereunder. 

8.       This Termination Agreement, and the terms, covenants and conditions hereof, shall be binding upon
and inure to the benefit of the Parties hereto and their respective successors and permitted assigns. 

9.       This Termination Agreement shall be governed by and interpreted in accordance with the laws of
England and Wales. The Convention for the International Sale of Goods shall not apply to this Termination Agreement and is hereby expressly disclaimed. 
 10.     Each Party hereto shall bear their own attorneys’ fees, costs, and expenses in connection with the negotiation for and preparation of this Termination Agreement, and the
completion of the termination as herein provided. 
 11.     Each Party hereto represents and warrants that
it is fully authorized to enter into this Termination Agreement and to carry out the obligations provided for herein. 

 12.     A waiver by a Party of any of the terms and conditions of this
Termination Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. 
 13.     Whenever possible, each provision of this Termination Agreement shall be interpreted in such manner as to be effective and valid to the fullest extent permitted under
applicable Law, but if one or more provisions of this Termination Agreement are held to be unenforceable or invalid under or in contravention of applicable Law by any court of competent jurisdiction, such provision shall be interpreted to the
fullest extent permitted by applicable Law, and the Parties shall negotiate in good faith to replace such provision with a provision which effects to the fullest extent possible the original intent of such provision. 

14.     This Termination Agreement constitutes the entire agreement of the Parties concerning the subject matter
hereof, superseding all prior and contemporaneous proposals, negotiations, communications and agreements, written or oral, with respect to the subject matter of this Termination Agreement. 

15.     This Termination Agreement may be executed in two (2) counterparts, each of which shall be deemed an
original but which together shall constitute one (1) and the same instrument. This Termination Agreement may be executed by facsimile or “PDF” signatures, which signatures shall have the same force and effect as original signatures.

 IN WITNESS WHEREOF, the Parties have caused this Termination Agreement to be executed and delivered by their respective duly
authorized officers as of the date first above written. 
  

									
	THERATECHNOLOGIES INC.	 		 	FERRER INTERNACIONAL, S.A.
					
	By:	 	(signed) Luc Tanguay	 		 	By:	 	(signed) Jorge Ramentol Massana
	Name:	 	Luc Tanguay	 		 	Name:	 	Jorge Ramentol Massana
	Title:	 	President and Chief Executive Officer	 		 	Title:	 	Chief Executive Officer
					
	By:	 	(signed) Jocelyn Lafond	 		 	By:	 	(signed) Antonio Villaro Martin
	Name:	 	Jocelyn Lafond	 		 	Name:	 	Antonio Villaro Martin
	Title:	 	Vice President, Legal Affairs	 		 	Title:	 	Chief Operating Officer
					
	Date:	 	5/4/13	 		 	Date:	 	2/4/13
				
	THERATECHNOLOGIES EUROPE INC.	 		 		 	
					
	By:	 	(signed) Luc Tanguay	 		 		 	
	Name:	 	Luc Tanguay	 		 		 	
	Title:	 	President	 		 		 	
					
	Date:	 	5/4/13	 		 		 	

 SCHEDULE “A” 

Press Release 

Theratechnologies Announces Termination of Agreement with Ferrer in Europe 
 Montréal, Canada –   —  , 2013 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) today
announced the termination of its distribution and licensing agreement with Ferrer Internacional, S.A. (Ferrer) for the commercialization of tesamorelin in Europe, Russia, South Korea, Taiwan and certain Asian countries for the treatment of excess
abdominal fat in HIV-infected patients with lipodystrophy. Ferrer was also responsible for regulatory activities for tesamorelin in these territories. 
 “We have been working diligently to forge the most appropriate path for tesamorelin in Europe following the withdrawal of our application last June. Our work in this regard continues and, at this
juncture, Ferrer and Theratechnologies have mutually agreed to terminate their agreement,” stated Luc Tanguay, President and Chief Executive Officer of Theratechnologies. 
 “We are currently working with key physicians, patient groups, regulatory consultants and certain regulators to assess a potential re-filing in Europe for tesamorelin. We will finalize our
resubmission strategy in this territory once our ongoing evaluation of the merits of each available option is completed. This includes an analysis of both a centralized and decentralized approach,” stated Luc Tanguay, President and Chief
Executive Officer of Theratechnologies. 
 As a result of the termination of this agreement, Theratechnologies, through its wholly-owned
subsidiary, now holds 100% of the commercialization rights for tesamorelin in Europe, Russia, South Korea, Taiwan and certain Asian countries. 

Currently there are no approved treatments for lipodystrophy in HIV-infected patients available in Europe. 

About Theratechnologies 

Theratechnologies (TSX: TH) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on
growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company’s website at www.theratech.com, on SEDAR at www.sedar.com and on the Securities and Exchange Commission’s
website at www.sec.gov. 
 Forward-Looking Information 
 This press release contains certain statements that are considered “forward-looking information” within the meaning of applicable securities legislation. This forward-looking information
includes, but is not limited to, information regarding the potential re-filing of a marketing authorization application for tesamorelin in Europe and the approval of tesamorelin in Europe for the treatment of excess abdominal fat in adult
HIV-infected patients with lipodystrophy. 
 Forward-looking information is based upon a number of assumptions and is subject to a number of
risks and uncertainties, many of which are beyond Theratechnologies’ control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include, but
are not limited to, that we will re-file a marketing 

 
authorization in Europe or in certain European countries only, that regulatory agencies in Europe will approve tesamorelin for the treatment of excess abdominal fat in adult HIV-infected patients
with lipodystrophy, that our third-party supplier of tesamorelin will have the capacity to manufacture and deliver tesamorelin to meet market demand, that our third-party supplier of tesdamorelin will be approved to manufacture products for resale
in Europe, that no conflict will occur with our commercial partners in other territories and that we will have our own sales force or an agreement with a third party to distribute ans sell tesamorelin in Europe, if approved. These risks and
uncertainties include, but are not limited to, the risk that we do not re-file a marketing authorization application for tesamorelin in Europe or in certain European countries only, that European regulatory agencies do not approve tesamorelin for
the treatment of excess abdominal fat in adult HIV-infected patients with lipodystrophy, that our third-party supplier of tesamorelin is unable or is not qualified to manufacture products for resale in Europe, that tesamorelin is subject to a recall
or market withdrawal, that conflicts occur with our commercial partners which will divert management’s attention, that we have no sales force or are unable to enter into an agreement with a third party for the distribution and sale of
tesamorelin in Europe upon terms commercially acceptable to us. 
 Theratechnologies refers potential investors to the “Risk Factors”
section of its Annual Report on Form 20-F dated February 26, 2013. The Annual Report on Form 20-F is available at www.sedar.com and at www.sec.gov under Theratechnologies’ public filings. The reader is cautioned to consider
these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and
represents Theratechnologies’ expectations as of that date. 
 Theratechnologies undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable laws. 
 Contact: 
 Denis Boucher 
 NATIONAL Public Relations 
 Phone: 514 843-2393

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]